Ex VivoExpansion of Murine MSC Impairs Transcription Factor-Induced Differentiation into Pancreaticβ-Cells
Open Access
- 10 March 2019
- journal article
- research article
- Published by Wiley in Stem Cells International
- Vol. 2019, 1-15
Abstract
Combinatorial gene and cell therapy as a means of generating surrogateβ-cells has been investigated for the treatment of type 1 diabetes (T1D) for a number of years with varying success. One of the limitations of current cell therapies for T1D is the inability to generate sufficient quantities of functional transplantable insulin-producing cells. Due to their impressive immunomodulatory properties, in addition to their ease of expansion and genetic modificationex vivo, mesenchymal stem cells (MSCs) are an attractive alternative source of adult stem cells for regenerative medicine. To overcome the aforementioned limitation of current therapies, we assessed the utility ofex vivoexpanded bone marrow-derived murine MSCs for their persistence in immune-competent and immune-deficient animal models and their ability to differentiate into surrogateβ-cells. CD45-/Ly6+murine MSCs were isolated from the bone marrow of nonobese diabetic (NOD) mice and nucleofected to express the bioluminescent protein,Firefly luciferase (Luc2). The persistence of a subcutaneous (s.c.) transplant ofLuc2-expressing MSCs was assessed in immune-competent (NOD) () and immune-deficient (NOD/Scid) () animal models of diabetes.Luc2-expressing MSCs persisted for 2 and 12 weeks, respectively, in NOD and NOD/Scidmice.Ex vivoexpanded MSCs were transduced with the HMD lentiviral vector (MOI = 10) to express furin-cleavable human insulin (INS-FUR) and murineNeuroD1andPdx1. This was followed by the characterization of pancreatic transdifferentiation via reverse transcriptase polymerase chain reaction (RT-PCR) and static and glucose-stimulated insulin secretion (GSIS).INS-FUR-expressing MSCs were assessed for their ability to reverse diabetes after transplantation into streptozotocin- (STZ-) diabetic NOD/Scidmice ().Transduced MSCs did not undergo pancreatic transdifferentiation, as determined by RT-PCR analyses, lacked glucose responsiveness, and upon transplantation did not reverse diabetes. The data suggest thatex vivoexpanded MSCs lose their multipotent differentiation potential and may be more useful as gene therapy targets prior to expansion.
Keywords
Funding Information
- Diabetes Australia Research Trust
- Rebecca L. Cooper Medical Research Foundation
This publication has 47 references indexed in Scilit:
- Combined Transfection of the Three Transcriptional Factors, PDX-1, NeuroD1, and MafA, Causes Differentiation of Bone Marrow Mesenchymal Stem Cells into Insulin-Producing CellsExperimental Diabetes Research, 2012
- Treatment of Type 1 Diabetes With Adipose Tissue–Derived Stem Cells Expressing Pancreatic Duodenal Homeobox 1Stem Cells and Development, 2009
- Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cellsBMC Cell Biology, 2008
- Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem CellsStem Cells, 2008
- Lentiviral-Transduced Human Mesenchymal Stem Cells Persistently Express Therapeutic Levels of Enzyme in a Xenotransplantation Model of Human DiseaseStem Cells, 2008
- Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapiesMechanisms of Ageing and Development, 2008
- Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapyDiabetologia, 2007
- Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cellsNature Biotechnology, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Mesenchymal Stem Cells in the Wharton's Jelly of the Human Umbilical CordStem Cells, 2004